[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uveitis-posterior\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uveitis-posterior":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100625500","frequency-and-intensity-of-inflammatory-relapses-in-patients-with-non-infectious-posterior-uveitis-treated-with-a-fluocinolone-acetonide-implant-100625500",false,"NCT07423442","Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant","Frequency and Intensity of REcurrences in Non-infectious Posterior Uveitis Treated With Fluocinolone Acetonide Implant (FACi): a Multicenter Retrospective Real-world Study","FIRE","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Diagnosis of non-infectious uveitis with posterior segment involvement\n* Presence of uveitic macular edema or persistent posterior segment inflammation\n* Treatment with a fluocinolone acetonide intravitreal implant prior to January 2024\n\nExclusion Criteria:\n\n* Infectious uveitis\n* Refusal to participate or documented opposition to the study\n* Follow-up duration shorter than 12 months after implantation","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","Non-infectious posterior uveitis is a chronic inflammatory eye disease that can lead to irreversible retinal damage and visual impairment due to repeated inflammatory relapses.\n\nThe fluocinolone acetonide intravitreal implant is approved for the prevention of inflammatory relapses in this condition, but data from real-world clinical practice remain limited, particularly regarding the intensity of relapses over time.\n\nThis multicenter retrospective observational study aims to evaluate the frequency and intensity of inflammatory recurrences in adult patients with non-infectious posterior uveitis treated with a fluocinolone acetonide implant. Clinical and imaging data routinely collected during follow-up will be analyzed over a three-year period to better characterize long-term outcomes, treatment burden, and safety in real-life conditions.",[25,26,27],"Noninfectious Posterior Uveitis","Uveitis, Posterior","Uveitic Macular Edema","NOT_YET_RECRUITING","2026-06-23",{"date":31,"type":32},"2026-06-24","ACTUAL",{"date":34,"type":21},"2026-06",{"date":36,"type":21},"2027-01",{"name":38,"class":39},"Nantes University Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100476632","phase-3-the-use-of-two-yutiq-versus-sham-for-treatment-of-chronic-non-infectious-intraocular-inflammation-affecting-the-posterior-segment-100476632","NCT05486468","The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment","The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)","TYNI","Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n1. Male or non-pregnant female in good general health at least 18 years of age, understands the language of the informed consent, and is willing and able to provide written informed consent and sign\u002Fdate a health information release (HIPAA form) before any study procedures are performed.\n2. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n\nOcular Inclusion Criteria (Study Eye):\n\n1. Diagnosed with chronic unilateral or bilateral noninfectious posterior segment inflammation (with or without anterior uveitis) that demonstrated a clinical response to ≥1 previous corticosteroid treatment of any localized type (eg, topical steroid 2 to 4 times per day or intra- or peri-ocular injection) or systemic corticosteroid\u002Fimmunosuppressant treatment with recurrence following treatment indicating chronicity according to the Investigator's judgment.\n2. Presence of active posterior segment inflammation as determined by the Investigator.\n3. Vitreous haze grade ≥ 2 based on the standardization of uveitis nomenclature (SUN) criteria.\n4. Less than 10 anterior chamber cells\u002Fhigh power field determined by slit lamp examination.\n5. Not planning to undergo elective ocular surgery during the study.\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria:\n\n1. Subjects with known hypersensitivity to any components of YUTIQ.\n2. Female subjects who are pregnant or breastfeeding.\n3. Has any acute or chronic medical disease or psychiatric condition that, in the opinion of the Investigator, would preclude participation in the study or put the subject at risk due to study treatment or procedures.\n\nOcular Exclusion Criteria (Study Eye):\n\n1. History of anterior uveitis only (without associated uveitis that affected the posterior segment).\n2. Presence of a vitreous hemorrhage.\n3. Uveitis with infectious etiology.\n4. Intraocular inflammation associated with a condition other than non-infectious uveitis (e.g., intraocular lymphoma).\n5. Current infectious diseases of the cornea and conjunctiva, mycobacterial infections of the eye, or fungal diseases of ocular structures.\n6. Subjects with ACIOL (Anterior Chamber Intraocular Lens) or rupture of the posterior lens capsule.\n7. Diagnosis of any form of glaucoma or ocular hypertension at screening, unless the study eye is being treated with ≤2 intraocular pressure (IOP)-lowering medications and\u002For has been previously treated with an incisional surgical procedure resulting in stable IOP in the normal range (10 to 21 mmHg).\n8. Intraocular pressure \\>21 mmHg or concurrent therapy at screening with \\>2 IOP-lowering pharmacologic agents in the study eye.\n9. Any eye surgery within 12 weeks prior to Day 1 of the study.\n10. Subjects who are unable to attend scheduled follow-up visits throughout the 12-month study.\n11. Has a significant media opacity precluding evaluation of retina and vitreous in the study eye.",{"count":50,"type":21},30,"INTERVENTIONAL",[53],"PHASE3","The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)",[56,26,57,58],"Uveitis","Uveitis, Anterior","Uveitis, Intermediate","RECRUITING","2025-08-06",{"date":62,"type":32},"2025-08-11",{"date":64,"type":32},"2022-10-05",{"date":66,"type":21},"2026-12",{"name":68,"class":39},"Texas Retina Associates",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100573255","role-of-oct--oct-angiography-in-patients-with-posterior-at-the-uveitis-clinic-of-assiut-university-hospital-100573255","NCT06743906","Role of OCT & OCT Angiography in Patients With Posterior at the Uveitis Clinic of Assiut University Hospital.","Inclusion Criteria:\n\n* \\- Patient age of greater than 18 years old.\n* Patient can offer viable consent.\n* Patient with posterior uveitis (infectious or non-infectious posterior uveitis).\n\nExclusion Criteria:\n\n* \\- Patient unable to offer viable consent.\n* Patient unwilling to participate.\n* Any coexistence retinal pathology: diabetic retinopathy, other causes of retinal vascular occlusion, traumatic retinopathy, traumatic maculopathy, other peripheral ischemic retinopathy e.g. sickles cell retinopathy.\n* Presence of media opacity hindering appropriate scan.",{"count":76,"type":21},25,"OCT angiography is a recent evaluation of OCT technology which combines the structural assessment of ocular tissues obtained by OCT image with visualization of blood flow within the vessels in imaged area. So combined structural and function image can be obtained by OCT angiography.\n\nDefferent type of uveitis often have specific OCT \\& OCT angiography findingwhich deffer according to the involved ocular tissue and according to the type of inflammatory \u002F infectious process that characterize them.\n\nThe aim of study is to determine the role of OCT \\& OCT angiography in assessment of retinal and choroidal architectural and vascular changes in patients with posterior uveitis.",[26],[80],"OCT & OCT angiography","2025-04-17",{"date":83,"type":32},"2025-04-21",{"date":85,"type":21},"2025-05-01",{"date":87,"type":21},"2026-05-01",{"name":89,"class":39},"Assiut University"]